Press releases

Success of the Simplified Cash Tender Offer for the Shares and bons the souscription d’actions of Novagali Pharma SA by Santen Pharmaceutical Co., Ltd - 2011/12/22
Santen Pharmaceutical Co., Ltd. (« Santen ») and Novagali Pharma SA (« Novagali ») announced today the success of the simplified cash tender offer for the shares and bons de souscription d’actions (“BSAs”) of Novagali initiated by Santen. The Autorité des Marchés Financiers (“AMF”) published today the results of the Offer which took place from December 2, 2011 to December 15, 2011 included. Over the course of the Offer, 7,545,247 shares, 700 2014 BSAs and 5,406 2019 BSAs have been tendered, for €6.15 (...)
VitamFero and Oniris have signed an agreement to study the efficacy of a vaccine candidate against neosporosis - 2011/12/06
VitamFero, a biotechnology firm in the Genopole cluster that develops novel vaccines to prevent specific parasitic diseases, and Oniris, an institute of higher education and specialized research, particularly in human and animal health, announced the signing of a services contract to study the efficacy of a new generation vaccine candidate against bovine (cattle) neosporosis.
Global Bioenergies and LanzaTech launch a collaboration to assess the bioproduction of isobutene from carbone monoxide
Global Bioenergies and LanzaTech Ltd, two industrial biology companies, today announce the beginning of a feasibility study to examine whether Global Bioenergies’ pathway, leading to the direct production of isobutene, can be functionally transferred into LanzaTech’s carbon monoxide using organism.
BioQuanta and Gentronix announce commercial partnership covering commercialization of the Mitoxis® functional metabolic platform - 2011/11/17
BioQuanta SA, a French company engaged in the implementation of predictive and personalized medicine and Gentronix Limited, the specialist genotoxicity assay provider, are pleased to announce the signing of a commercial agreement covering the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Global Bioenergies enters into an agreement with a German car manufacturer - 2011/11/14
Global Bioenergies (FR0011052257 – NYSE Alternext : ALGBE), today announces the signature of an agreement with a major German car manufacturer regarding an undisclosed application of its technology.
Global Bioenergies deploys its R&D platform - 2011/10/27
Global Bioenergies S.A. (FR0011052257 – NYSE Alternext : ALGBE), an industrial biology company developing sustainable routes to light olefins, today announces the extension of its R&D platform.

[+] Previous page